RxDoctor Payments DataLook up a doctor →

Jeffrey Chasteen, DO

Family Medicine · Tulsa, OKNPI 1427081520

Payments from drug & device makers

$820,233in general payments, 2019–2025

Across 578 payments — averaging $1419.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$430K
  • Eli Lilly$174K
  • Janssen Research & Development, LLC$90K
  • Sanofi US Services Inc.$61K
  • Bristol Myers Squibb$59K
  • Kowa Pharmaceuticals America, Inc.$925
  • plus $6K from 44 others
$625in research payments, 2019–2025

Across 3 payments — averaging $208.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$625

What the payments were for

  • Food & beverage$6,750100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$820,233 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$1,977
Medicare patients
13
Services billed
69

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide11$11,424
Rosuvastatin Calcium37$706
Pantoprazole Sodium20$351
Gabapentin25$330
Metoprolol Succinate25$295
Pentoxifylline16$293
Atorvastatin Calcium13$283
Trazodone Hcl27$268
Tamsulosin Hcl12$265
Sertraline Hcl18$223
Memantine Hcl12$197
Montelukast Sodium19$192
Losartan Potassium21$190
Allopurinol15$186
Amlodipine Besylate26$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$796$11,42411 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$36$12424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →